PhoreMost Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Employees
  • 50

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $46M

  • Investors
  • 15

PhoreMost General Information

Description

Developer of a drug target identification platform intended to identify new targets or drugs for future therapy. The company's platform provides cryptic druggable sites in the human genome and directly links them to useful therapeutic functions in a live-cell context and then uses these functionally validated protein fragments to rapidly inform the design of small molecule drugs with the same shape, enabling medical practitioners to continue the pipeline of highly validated first-in-class drug discovery programs for out-licensing to pharma.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • Unit 7, The Works
  • Unity Campus
  • Pampisford CB22 3FT
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PhoreMost Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 23-Mar-2021 $46M 000.00 00000 Completed Generating Revenue
5. Early Stage VC (Series A) 30-Apr-2018 000.00 000.00 000.00 Completed Pre-Clinical Trials
4. Grant 27-Apr-2018 00.000 Completed Pre-Clinical Trials
3. Early Stage VC 03-Mar-2017 00.000 00.000 000.00 Completed Pre-Clinical Trials
2. Grant 13-May-2015 $2.14M $6.12M Completed Pre-Clinical Trials
1. Seed Round 11-Mar-2015 $6.12M $6.12M Completed Pre-Clinical Trials
To view PhoreMost’s complete valuation and funding history, request access »

PhoreMost Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A1 Ordinary 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
A Ordinary 0,000 00.000000 00.00 00.00 00 00.00 0.000
A Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
A Ordinary 46,700 $0.001393 $59.66 $59.66 1x $59.66 7.83%
A Ordinary 65,311 $0.001393 $54.18 $54.18 1x $54.18 10.96%
To view PhoreMost’s complete cap table history, request access »

PhoreMost Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug target identification platform intended to identify new targets or drugs for future therapy. The com
Discovery Tools (Healthcare)
Pampisford, United Kingdom
50 As of 2023
000.00
0000 0000-00-00
00000000000 000.00

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labor
0000 000000000
Quincy, MA
00 As of 0000
000
0000 0000-00-00
000000&0 000

00000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conse
0000000000000
San Diego, CA
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PhoreMost Competitors (68)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abveris Formerly VC-backed Quincy, MA 00 000 000000&0 000
00000 0000000 0000 Formerly VC-backed San Diego, CA 00 000.00 00000000000 000.00
000000 000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 68 competitors. Get the full list »

PhoreMost Patents

PhoreMost Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202111193-D0 Pharmaceutical compounds Pending 03-Aug-2021 000000000
GB-202110820-D0 Targeted protein degradation Inactive 28-Jul-2021
EP-3969605-A1 Method of screening for peptides capable of binding to a ubiquitin protein ligase (e3) Pending 13-May-2019 0000000000
GB-201906705-D0 Methods Inactive 13-May-2019 0
US-20220236273-A1 Method of screening for peptides capable of binding to a ubiquitin protein ligase (e3) Pending 13-May-2019 G01N33/574
To view PhoreMost’s complete patent history, request access »

PhoreMost Executive Team (10)

Name Title Board Seat Contact Info
Neil Torbett Ph.D Chief Executive Officer & Board Member
Andrew Muncey Chief Financial Officer
Benedict Cross Ph.D Chief Technology Officer
Christian Dillon Chief Scientific Officer
Charli Batley Ph.D Chief of Staff and Vice President of Operations
You’re viewing 5 of 10 executive team members. Get the full list »

PhoreMost Board Members (12)

Name Representing Role Since
Alastair Kilgour Parkwalk Advisors Board Member 000 0000
Catherine Beech MD Self Chairman 000 0000
Christopher Torrance Ph.D PhoreMost Co-Founder & Chairman 000 0000
Gerald Chan Ph.D Morningside Group Board Member 000 0000
Hermann Hauser Ph.D Amadeus Capital Partners Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

PhoreMost Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PhoreMost Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5Y Capital Venture Capital Minority 000 0000 000000 0
Astellas Venture Management Corporate Venture Capital Minority 000 0000 000000 0
BGF Growth/Expansion Minority 000 0000 000000 0
Trend Investment Group Venture Capital Minority 000 0000 000000 0
XtalPi VC-Backed Company Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »